From Karl Wurm and Guy Scadding's staging to 18F-FDG PET/CT scan phenotyping and far beyond: perspective in the evading history of phenotyping in sarcoidosis
暂无分享,去创建一个
J. Grunewald | E. Gialafos | S. Papiris | A. Papaioannou | E. Manali | A. Georgakopoulos | S. Chatziioannou | M. Kallieri | L. Kolilekas | V. Apollonatou | N. Rivera | E. Antonogiannaki | Guoping Li | T. Raptakis | E. Chatterjee | P. Gokulnath | M. Spanos
[1] C. Bock,et al. Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation , 2023, Immunity.
[2] S. Liao,et al. Multi-Omic Signatures of Sarcoidosis and Progression in Bronchoalveolar Lavage Cells , 2023, bioRxiv.
[3] J. Grutters,et al. Infliximab decreases inflammatory activity but has no effect on small fiber neuropathy related symptoms in Dutch patients with sarcoidosis , 2022, Sarcoidosis Vasculities and Diffuse Lung Diseases.
[4] M. Walker,et al. Hypercalcemia: A Review. , 2022, JAMA.
[5] J. DeWitt,et al. Neurosarcoidosis: Phenotypes, Approach to Diagnosis and Treatment , 2022, Current Rheumatology Reports.
[6] D. Jiang,et al. A transcriptomics-based meta-analysis identifies a cross-tissue signature for sarcoidosis , 2022, Frontiers in medicine.
[7] Chieh-Yu Lin,et al. Transcriptional and Immune Landscape of Cardiac Sarcoidosis , 2022, Circulation research.
[8] J. Grutters,et al. ANXA11 rs1049550 Associates with Löfgren’s Syndrome and Chronic Sarcoidosis Patients , 2022, Cells.
[9] C. D. Dela Cruz,et al. Emerging insights in sarcoidosis: moving forward through reverse translational research. , 2022, American journal of physiology. Lung cellular and molecular physiology.
[10] F. Cipollone,et al. Clinical Features, Histopathology and Differential Diagnosis of Sarcoidosis , 2021, Cells.
[11] S. Liao,et al. The landscape of transcriptomic and proteomic studies in sarcoidosis , 2021, ERJ Open Research.
[12] R. Baughman,et al. Management of Advanced Pulmonary Sarcoidosis. , 2021, American journal of respiratory and critical care medicine.
[13] J. Grunewald,et al. Differences in disease presentation between men and women with sarcoidosis: A cohort study , 2021, Respiratory Medicine.
[14] H. Dai,et al. Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019 , 2021, Thorax.
[15] T. Fingerlin,et al. Clinical phenotyping in sarcoidosis using cluster analysis , 2021, Respiratory Research.
[16] Marc A. Judson. Granulomatous Sarcoidosis Mimics , 2021, Frontiers in Medicine.
[17] M. Judson. A Primer on the Clinical Aspects of Sarcoidosis for the Basic and Translational Scientist , 2021, Journal of clinical medicine.
[18] P. Spagnolo,et al. Genetics in sarcoidosis , 2021, Current opinion in pulmonary medicine.
[19] J. Grunewald,et al. Bronchoalveolar lavage fluid cell subsets associate with the disease course in Löfgren's and non-Löfgren's sarcoidosis patients. , 2021, Respiratory medicine.
[20] Alexander G. Mathioudakis,et al. ERS clinical practice guidelines on treatment of sarcoidosis , 2021, European Respiratory Journal.
[21] L. Calandriello,et al. Novelties in Imaging of Thoracic Sarcoidosis , 2021, Journal of clinical medicine.
[22] T. Fingerlin,et al. Genomic biomarkers in chronic beryllium disease and sarcoidosis. , 2021, Respiratory medicine.
[23] D. Fraidenburg,et al. Unsupervised Clustering Reveals Sarcoidosis Phenotypes Marked by a Reduction in Lymphocytes Relate to Increased Inflammatory Activity on 18FDG-PET/CT , 2021, Frontiers in Medicine.
[24] F. Akdim,et al. Effectiveness and safety of infliximab in cardiac Sarcoidosis. , 2021, International journal of cardiology.
[25] G. Spyropoulos,et al. Clinical, imaging and functional determinants of sarcoidosis phenotypes in a Greek population , 2021, Journal of Thoracic Disease.
[26] Xin Xu,et al. Value of 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospective study , 2021, Translational lung cancer research.
[27] Mark M. Davis,et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19 , 2020, Cell.
[28] I. Annesi-Maesano,et al. Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort , 2020, European Respiratory Journal.
[29] Z. Fayad,et al. Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.
[30] M. Judson. Screening Sarcoidosis Patients for Occult Disease , 2020, Seminars in Respiratory and Critical Care Medicine.
[31] M. Becich,et al. Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis , 2020, European Respiratory Journal.
[32] E. Arkema,et al. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. , 2020, Current opinion in pulmonary medicine.
[33] C. Montgomery,et al. Recent advances in sarcoidosis genomics: epigenetics, gene expression, and gene by environment (G × E) interaction studies. , 2020, Current opinion in pulmonary medicine.
[34] P. Spagnolo,et al. Looking into the future of sarcoidosis: what is next for treatment? , 2020, Current opinion in pulmonary medicine.
[35] M. Kallergi,et al. Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study , 2020, Expert review of respiratory medicine.
[36] Brian E. Vestal,et al. Comparative Profiling of the Immune System in Sarcoidosis via CITE-Seq and Flow Cytometry , 2020, Journal of Immunology.
[37] R. Blankstein,et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.
[38] M. Scholand,et al. Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry , 2020, European Respiratory Journal.
[39] M. Okano,et al. Cohort Study , 2020, Definitions.
[40] M. Kallergi,et al. Emerging phenotypes of sarcoidosis based on 18F-FDG PET/CT: a hierarchical cluster analysis , 2020, Expert review of respiratory medicine.
[41] M. Kallergi,et al. 18F-FDG PET/CT in Pulmonary Sarcoidosis:Quantifying Inflammation by the TLG index , 2020, Expert review of respiratory medicine.
[42] L. Alfredsson,et al. A Gene–Environment Interaction Between Smoking and Gene polymorphisms Provides a High Risk of Two Subgroups of Sarcoidosis , 2019, Scientific Reports.
[43] J. Grunewald,et al. Sarcoidosis , 2019, Nature Reviews Disease Primers.
[44] J. Grunewald,et al. Moving target: shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder , 2019, European Respiratory Journal.
[45] E. Miller,et al. Repeatability and Optimization of FDG Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis. , 2019, JACC. Cardiovascular imaging.
[46] M. Judson. The diagnosis of sarcoidosis. , 2019, Current opinion in pulmonary medicine.
[47] M. Soussan,et al. Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis. , 2019, Clinical radiology.
[48] A. Białas,et al. Sarcoidosis and calcium homeostasis disturbances—Do we know where we stand? , 2019, Chronic respiratory disease.
[49] J. Grunewald,et al. Familial aggregation and heritability of sarcoidosis: a Swedish nested case−control study , 2018, European Respiratory Journal.
[50] J. Grutters,et al. Volumetric FDG PET analysis of global lung inflammation: new tool for precision medicine in pulmonary sarcoidosis? , 2018, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[51] R. Baughman,et al. It's time to evolve from Scadding: phenotyping sarcoidosis , 2018, European Respiratory Journal.
[52] J. Milanowski,et al. Phenotypes of organ involvement in sarcoidosis , 2018, European Respiratory Journal.
[53] J. Grunewald,et al. Löfgren's Syndrome: Diagnosis, Management, and Disease Pathogenesis , 2017, Seminars in Respiratory and Critical Care Medicine.
[54] V. Anttila,et al. SNP Variants in Major Histocompatibility Complex Are Associated with Sarcoidosis Susceptibility—A Joint Analysis in Four European Populations , 2017, Front. Immunol..
[55] A. Aggarwal,et al. Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis. , 2016, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[56] E. Amin,et al. Severe Sarcoidosis Phenotypes: An Occupational Hazard? , 2016, Chest.
[57] Chao Lu,et al. Retrospective study , 2016, Medicine.
[58] Brian Quinn,et al. Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates , 2016, BMC Medical Imaging.
[59] J. Grunewald,et al. Expanded lung T-bet+RORγT+ CD4+ T-cells in sarcoidosis patients with a favourable disease phenotype , 2016, European Respiratory Journal.
[60] S. Walsh,et al. Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay , 2016, Insights into Imaging.
[61] M. Nöthen,et al. High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences. , 2016, American journal of respiratory and critical care medicine.
[62] L. Hubert,et al. Llllll Iii Ill Ii Ill1 Lllllll Lllllllll Ill1 Illi Swp 25/88 Issues to Be Addressed Prior to Undertaking Hierarchical Cluster Analysis A-prtort Weighting of Attributes? , 2000 .
[63] P. Spagnolo,et al. Immunogenetics of Disease-Causing Inflammation in Sarcoidosis , 2015, Clinical Reviews in Allergy & Immunology.
[64] P. Spagnolo. Sarcoidosis: a Critical Review of History and Milestones , 2015, Clinical Reviews in Allergy & Immunology.
[65] C. Lindskog,et al. Proteomic profiling reveals autoimmune targets in sarcoidosis. , 2015, American journal of respiratory and critical care medicine.
[66] M. Gazouli,et al. Relationship between tumor necrosis factor-α (TNFA) gene polymorphisms and cardiac sarcoidosis. , 2014, In vivo.
[67] Rajender Kumar,et al. Ocular sarcoidosis: does (18)F-FDG PET/CT have any role? , 2014, Clinical nuclear medicine.
[68] A. Prasse,et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. , 2014, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[69] A. Gabrielsen,et al. HLA-alleles associated with increased risk for extra-pulmonary involvement in sarcoidosis. , 2014, Tissue antigens.
[70] A. Nicholson,et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. , 2014, The Lancet. Respiratory medicine.
[71] A. Dua,et al. Images in clinical medicine. Heerfordt's syndrome, or uveoparotid fever. , 2013, The New England journal of medicine.
[72] J. Grutters,et al. Imaging the inflammatory activity of sarcoidosis , 2012, European Respiratory Journal.
[73] A. Prasse,et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. , 2011, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[74] K. Cederlund,et al. Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients , 2010, Respiratory research.
[75] D. Rontogianni,et al. The many faces of sarcoidosis: asymptomatic muscle mass mimicking giant-cell tumor , 2009, Rheumatology International.
[76] S. Lofgren. Primary pulmonary sarcoidosis. II. Clinical course and prognosis. , 2009, Acta medica Scandinavica.
[77] J. Grunewald,et al. Löfgren's syndrome: human leukocyte antigen strongly influences the disease course. , 2009, American journal of respiratory and critical care medicine.
[78] S. Papiris,et al. Subcutaneous Sarcoidosis Masquerading as Cellulitis , 2008, Dermatology.
[79] A. Constantinesco,et al. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[80] A. Prasse,et al. Phenotyping sarcoidosis from a pulmonary perspective. , 2008, American journal of respiratory and critical care medicine.
[81] M. Rossman,et al. Lesson learned from ACCESS (A Case Controlled Etiologic Study of Sarcoidosis). , 2007, Proceedings of the American Thoracic Society.
[82] R. Elston,et al. Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study , 2007, Genes and Immunity.
[83] P. Spagnolo,et al. Genetics of sarcoidosis. , 2007, Clinics in dermatology.
[84] Y. Nishiyama,et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[85] Bryan Langholz,et al. Case–Cohort Study , 2005 .
[86] M. Iannuzzi,et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. , 2003, American journal of human genetics.
[87] G. McLennan,et al. Clinical characteristics of patients in a case control study of sarcoidosis. , 2001, American journal of respiratory and critical care medicine.
[88] R. Baughman,et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[89] R. Loddenkemper,et al. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis--results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheitan. , 1998, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[90] N. Siafakas,et al. Pneumothorax as a first manifestation of sarcoidosis. , 1997, Chest.
[91] R. Crystal,et al. Increased numbers of T lymphocytes with gamma delta-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis. , 1990, The Journal of clinical investigation.
[92] R. Young,et al. Sarcoidosis--the beginning: historical highlights of personalities and their accomplishments during the early years. , 1984, Journal of the National Medical Association.
[93] R. Crystal,et al. Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. , 1983, The New England journal of medicine.
[94] J. Scadding. The late stages of pulmonary sarcoidosis , 1970, Postgraduate medical journal.
[95] J. Scadding. Prognosis of Intrathoracic Sarcoidosis in England , 1961, British medical journal.
[96] S. Lofgren. The concept of sarcoidosis. , 1961, American Review of Respiratory Disease.
[97] K. Wurm. [The significance of stage classification of sarcoidosis (Boeck's disease]. , 1960, Deutsche Medizinische Wochenschrift.
[98] W. Röntgen,et al. ON A NEW KIND OF RAYS. , 1896, Science.
[99] B. Barna,et al. Inflammatory Pathways in Sarcoidosis. , 2021, Advances in experimental medicine and biology.
[100] D. Okada,et al. Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis , 2018, Circulation. Cardiovascular imaging.
[101] R. Baughman,et al. Predictors of Mortality in Pulmonary Sarcoidosis , 2018, Chest.
[102] Pallewatte. Pictorial essay , 2016 .
[103] A. Dupuy,et al. [Heerfordt's syndrome]. , 2005, Presse medicale.
[104] G. Meier,et al. Zur Prognostik der Sarkoidose (Morbus Boeck) , 2005, Beiträge zur Klinik der Tuberkulose und spezifischen Tuberkulose-Forschung.
[105] Robert C. Wolpert,et al. A Review of the , 1985 .
[106] R. Crystal,et al. Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis. , 1982, Thorax.
[107] S. Lofgren,et al. The bilateral hilar lymphoma syndrome; a study of the relation to tuberculosis and sarcoidosis in 212 cases. , 1952, Acta medica Scandinavica.